ADMINISTERING
MEDICATIONS: 2025 RELEASE
• AUTHOR(S)DONNA
GAUWITZ
TEST BANK
1
Reference
Ch. 1 — Definition of Terms & Pharmacology
Stem
A 72-year-old patient with newly diagnosed hypertension asks
why the medication label lists a generic name and a different
brand name. The nurse is preparing the initial medication
teaching and must decide how to explain the difference while
verifying the order in the eMAR. Which nursing response or
action is best?
,A. Tell the patient brand and generic names are interchangeable
and administer per eMAR without further verification.
B. Explain that active ingredients are the same, confirm the
order's name (generic vs brand) in the eMAR, and document
the explanation in the plan of care.
C. Advise the patient to refuse the medication until the
prescriber signs a brand-specific order.
D. Administer the drug under the brand name only, since
patients prefer brand names, and omit any teaching to save
time.
Correct Answer
B
Rationale — Correct
Explaining that active ingredients are the same while confirming
the order in the eMAR demonstrates patient education,
medication safety, and appropriate verification of the
prescribed product. Documenting the teaching aligns with
nursing standards and supports continuity of care. This action
reduces confusion and prevents medication errors stemming
from name differences.
Rationale — Incorrect
A. Fails to provide patient education and omits confirming the
exact order in eMAR; risk of miscommunication.
C. Unnecessarily escalates care and may delay therapy;
prescriber clarification is only needed if order is unclear.
,D. Prioritizes preference over safety and omits required patient
teaching and documentation.
Teaching Point
Verify order name in eMAR; teach that generic and brand
contain same active ingredient.
Citation
Gauwitz, D. (2025). Administering Medications. Ch. 1.
2
Reference
Ch. 1 — Drug Sources & Drug Uses
Stem
A nurse reviewing a new medication order for an antibiotic
derived from a biological source notes the patient is
immunocompromised. Which nursing consideration most
appropriately guides the administration plan?
A. Proceed as usual; drug source is irrelevant to administration
decisions.
B. Consult the drug reference for routes, contraindications, and
immunologic risks, then monitor closely for adverse reactions.
C. Substitute a synthetic alternative without consulting
prescriber, because biological drugs are unsafe for
immunocompromised patients.
D. Delay administration indefinitely and notify the pharmacist
to cancel the order.
, Correct Answer
B
Rationale — Correct
Consulting a current drug reference addresses the nurse's
responsibility to understand a drug’s source, indications,
contraindications, and monitoring needs for high-risk patients.
For immunocompromised patients, biologic agents may have
unique adverse effects; close monitoring preserves safety while
ensuring timely therapy.
Rationale — Incorrect
A. Ignores important pharmacologic differences tied to drug
source that may affect safety.
C. Unauthorized substitution risks therapeutic failure and
legal/ethical violations.
D. Unnecessary delay risks harm from untreated infection;
cancellation requires prescriber/pharmacist collaboration.
Teaching Point
Use up-to-date drug references for biologic agents and monitor
high-risk patients closely.
Citation
Gauwitz, D. (2025). Administering Medications. Ch. 1.
3
Reference
Ch. 1 — Drug Standards & Drug Names
MEDICATIONS: 2025 RELEASE
• AUTHOR(S)DONNA
GAUWITZ
TEST BANK
1
Reference
Ch. 1 — Definition of Terms & Pharmacology
Stem
A 72-year-old patient with newly diagnosed hypertension asks
why the medication label lists a generic name and a different
brand name. The nurse is preparing the initial medication
teaching and must decide how to explain the difference while
verifying the order in the eMAR. Which nursing response or
action is best?
,A. Tell the patient brand and generic names are interchangeable
and administer per eMAR without further verification.
B. Explain that active ingredients are the same, confirm the
order's name (generic vs brand) in the eMAR, and document
the explanation in the plan of care.
C. Advise the patient to refuse the medication until the
prescriber signs a brand-specific order.
D. Administer the drug under the brand name only, since
patients prefer brand names, and omit any teaching to save
time.
Correct Answer
B
Rationale — Correct
Explaining that active ingredients are the same while confirming
the order in the eMAR demonstrates patient education,
medication safety, and appropriate verification of the
prescribed product. Documenting the teaching aligns with
nursing standards and supports continuity of care. This action
reduces confusion and prevents medication errors stemming
from name differences.
Rationale — Incorrect
A. Fails to provide patient education and omits confirming the
exact order in eMAR; risk of miscommunication.
C. Unnecessarily escalates care and may delay therapy;
prescriber clarification is only needed if order is unclear.
,D. Prioritizes preference over safety and omits required patient
teaching and documentation.
Teaching Point
Verify order name in eMAR; teach that generic and brand
contain same active ingredient.
Citation
Gauwitz, D. (2025). Administering Medications. Ch. 1.
2
Reference
Ch. 1 — Drug Sources & Drug Uses
Stem
A nurse reviewing a new medication order for an antibiotic
derived from a biological source notes the patient is
immunocompromised. Which nursing consideration most
appropriately guides the administration plan?
A. Proceed as usual; drug source is irrelevant to administration
decisions.
B. Consult the drug reference for routes, contraindications, and
immunologic risks, then monitor closely for adverse reactions.
C. Substitute a synthetic alternative without consulting
prescriber, because biological drugs are unsafe for
immunocompromised patients.
D. Delay administration indefinitely and notify the pharmacist
to cancel the order.
, Correct Answer
B
Rationale — Correct
Consulting a current drug reference addresses the nurse's
responsibility to understand a drug’s source, indications,
contraindications, and monitoring needs for high-risk patients.
For immunocompromised patients, biologic agents may have
unique adverse effects; close monitoring preserves safety while
ensuring timely therapy.
Rationale — Incorrect
A. Ignores important pharmacologic differences tied to drug
source that may affect safety.
C. Unauthorized substitution risks therapeutic failure and
legal/ethical violations.
D. Unnecessary delay risks harm from untreated infection;
cancellation requires prescriber/pharmacist collaboration.
Teaching Point
Use up-to-date drug references for biologic agents and monitor
high-risk patients closely.
Citation
Gauwitz, D. (2025). Administering Medications. Ch. 1.
3
Reference
Ch. 1 — Drug Standards & Drug Names
